Campbell Neurosciences Press Releases

trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Launches Campbell Neurosciences Division aimed at Biologically Identifying and Repairing Suicide-Prone Brains

Company Leverages Existing Immunology and Regenerative Medicine Intellectual Property to Attack Second Leading Cause of Death in Young People


8/11/20


https://www.prnewswire.com/news-release ... 10221.html


OCEANSIDE, Calif., Aug. 11, 2020 /PRNewswire/ — Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today formation of Campbell Neurosciences, a new division of the Company dedicated to approaching suicide as a biological disorder and developing science-based diagnostic tools and interventions.

The Division will be headed by Kalina O’Connor, and is named after her mother, Kathleen Campbell, who was a victim of suicide. Ms. O’Connor has previously worked in the area of drug and alcohol rehabilitation, as well as assisting the Company in its basic research and development.

Howard Leonhardt, a serial inventor and entrepreneur, whose inventions have treated over 500,000 patients in 60 countries will serve as Advisor to the Division. Additionally, Dr. Erin Ferma, a forensic psychologist with over 15 years clinical experience will provide input on clinical trial design and practical implementation of the technologies under development. Former Congressional Candidate and Director of Business Development, Famela Ramos, will oversee operations.

“I am honored to be working with Timothy Dixon, a modern-day renaissance man, and the team at Therapeutic Solutions International. This organization has developed products and conducted successful preclinical and clinical trials on approaches which can modulate biological pathways linked to suicide” said Ms. O’Connor. “By leveraging existing findings and developing new intellectual property, we believe we are in the position to offer for the first time a suicide risk score which is based on science and not psychological self-assessment. Combined with identifying risk, we seek to develop various therapeutic approaches.”

Previous studies have shown correlations between inflammatory cytokines in the blood and suicide. The causative effects of these molecules on suicidal ideation is seen in cancer patients who take similar molecules for hyperstimulation of immunity, which also results in suicidal ideation. Products developed by Therapeutic Solutions International such as NeuroStilbene™, NanoStilbene™ and QuadraMune™ have been shown to reduce inflammatory markers.

“It is extremely exciting to be at the ground floor of a paradigm shift” said Howard Leonhardt. “I look forward to assisting the Company in accelerating solutions for this terrible condition. Additionally, we will explore synergistic interaction with various companies form the Leonhardt Ventures portfolio.”

“Suicide has historically been treated as a stigma. With increasing advancement of science, we realize it is a biological abnormality and should be addressed the same way we address other conditions” said Timothy Dixon, President and CEO of the Company. “Psychiatry is the only discipline of medicine that does not base its drug prescriptions by detailed evaluation of the organ they are treating. It is interesting that only in psychiatry that treatments are given without actually assessing physical changes that the intervention is accomplishing. Technologies we are developing will provide a biological basis for the practice of psychiatry as it relates to suicide prevention.”

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com, and our public forum where all are welcome is https://board.therapeuticsolutionsint.com/

Therapeutic Solutions International, Inc.
ir@tsoimail.com

SOURCE Therapeutic Solutions International, Inc.
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Files Patent on Campbell Score™: The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers

Ending the Stigma of Suicide

8/21/20


https://www.prnewswire.com/news-release ... 16310.html


OCEANSIDE, Calif., Aug. 21, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), announced today filing a patent covering immunological means of quantifying risk of suicide. One embodiment of the patent is the Campbell Score™, a proprietary means of predicting risk of suicide based on assessment of immunological parameters from the blood of the patient.

"Since the beginning of time, suicide has been treated as a stigma, with victims being called 'selfish' and 'choosing the easy way out.' I am proud of the team and scientific advisors of Therapeutic Solutions International who have initiated the process of using solid science to establish suicide as an immunological disease," said Kalina O'Connor, Director of the Campbell Neurosciences Division of the Company and co-inventor of the patent. "By activating immune cells outside of the body using neurological chemicals, we can put our fingers on the pulse of the brain-immune interaction, which appears to be one of the critical factors controlling risk of suicide."

Kalina O'Connor's mother Kathleen Campbell was a victim of suicide. The name Campbell Score™ was chosen in her honor.

"It is estimated that a minimum of 1.5 million people will die from suicide in 2020. Furthermore, this is the second biggest cause of death for young people in the USA. At present the only means of evaluating suicidal tendencies are through questionnaires, which are often unreliable due to patient reluctance to share relevant information," said Famela Ramos, former Congressional Candidate, co-inventor on the patent and Director of Business Development. "Working with the Team assembled by Ms. O'Connor, including internationally renowned inventor Howard Leonhardt and psychologist Erin Ferma, positions the Company to initiate the paradigm shift needed to change the way we look at suicide."

"The potential of immune hyperactivation being related to suicidal risk has been known for decades. In the beginning days of cancer immunotherapy, observations were made that hyperactivation of immunity led to suicidal thoughts," stated Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "It is of great interest to the Company to explore using agents such as QuadraMune™ in patients with inflammation associated suicidal ideations given that QuadraMune™ reduces interleukin-6, which is one of the components of the Campbell Score™."

"We are extremely thankful for our advisors and collaborators, and especially to Ms. O'Connor whose labor of love for her late mother has stimulated such scientific progress," said Timothy Dixon, President and CEO of the Company and co-inventor. "Given that we are already running a COVID-19 prevention trial using QuadraMune™, it will be exciting to explore the use of QuadraMune™ for prevention of suicidal ideations and to document reduction of the Campbell Score™ in clinical trials.

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com , and our public forum is https://board.therapeuticsolutionsint.com/

Therapeutic Solutions International, Inc.
ir@tsoimail.com

SOURCE Therapeutic Solutions International, Inc.
Related Links

https://therapeuticsolutionsint.com/
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune™ and Minocycline

Campbell Neurosciences Division Continues its Mission of "Treating Suicide as a Biological Disease"


8/28/20

https://www.prnewswire.com/news-release ... 20336.html


OCEANSIDE, Calif., Aug. 28, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported filing a patent on new data showing synergy between QuadraMune™ and Minocycline in generating a type of immune cell termed T regulatory cell.

T regulatory cells suppress pathological inflammation, including interleukin-6, which is associated with suicidal ideation, as well as risk of COVID-19 associated death.

QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.

"The recent data supports initiation of clinical trials combining QuadraMune and Minocycline for reduction of suicidal ideations and hopefully preventing suicides" said Kalina O'Connor, Director of the Campbell Neurosciences Division of Therapeutic Solutions International and co-inventor of the patent. "I am thankful to Mr. Dixon and the team at TSOI for having the courage to attack suicide as a biological disease."

Campbell Neurosciences was formed as a Division of the Company to address suicide from an immunological perspective. The company is named after Kathleen Campbell, the mother of Kalina O'Connor, who was a victim of suicide.

"The potent generation of T regulatory cells by the combination of QuadraMune™ and Minocycline suggests that the therapeutic effects of the combination may be long lasting due to the fact that T regulatory cells have a long life in the body and can replicate" said Famela Ramos, Director of Business Development. "The ability of the T regulatory cells generated to suppress interleukin-6 and macrophage activation supports the possible use of this combination for other neurogenerative diseases associated with inflammation."

"By combining quantitative measurements such as the Campbell Score™, with practical interventions such as QuadraMune™ with adjuvants such as Minocycline, we believe that we are primed for initiating a new way of treating suicide based on objective immunology and not speculation" said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "We thank our Scientific Advisory Board for their leadership in stimulating us to explore this fascinating and underdeveloped area of medicine."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

[1] https://clinicaltrials.gov/ct2/show/NCT04421391

Therapeutic Solutions International, Inc.
ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Files Comprehensive Campbell Platform™ Patent for Stem Cell Immunotherapy of Schizophrenia

Campbell Neurosciences Division Continues Groundbreaking Work Based on Treating Suicide as a Biological Disease


9/14/20

https://www.prnewswire.com/news-release ... 30078.html


OCEANSIDE, Calif., Sept. 14, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today filing of a landmark patent, with over 1000 claims, covering stem cell based immunotherapy of schizophrenia, one of the significant causes of suicide. The patent, based on years of biochemical, neurological and cellular research by the inventors covers utilization of various stem cell types, as well as cellular immunotherapies, nutraceuticals, and small molecules, for reducing symptoms and increasing treatment responsiveness in schizophrenic patients.

"Schizophrenia, despite affecting approximately 1% of the population, is still treated in a very empirical manner with little understanding of the molecular mechanisms of the disease or the currently used treatments" said Kalina O'Conner, Director of Campbell Neurosciences and co-inventor of the patent. "We are proud to have developed a novel, science-based, platform for therapeutic intervention which is grounded in objective assessment and intervention methods."

The Campbell Platform™ is an extension of earlier work described by the Company as the Campbell Score™, in which inflammatory markers, exosomes, and imaging technologies are initially used to provide an integrative means of evaluating disease status. Once the unique aspects of each patient's disease are understood, a personalized approach is developed to address their own unique needs.

"The JadiCell has been demonstrated to possess exceptional anti-inflammatory and immune modulatory activity. We are extremely excited to apply these properties to the area of neurology" said Dr. Amit Patel, co-inventor of the patent, and inventor of the JadiCell. "Having exclusively licensed certain neurologically related aspects of the JadiCell Universal donor stem cell technology to the Company, I am excited about these new developments and strongly support the current work in progress associated with suicide, brain injury, and chronic traumatic encephalopathy."

In December 2018 Therapeutic Solutions International signed an agreement with Jadi Cell LLC for licensing of the JadiCell universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2 for use in Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI)1.

"It is truly amazing to see the dedication of our Team and Scientific Advisors at rapidly translating ideas to patents, to preclinical research and to INDs" said Timothy Dixon, President and CEO of the Company, as well as co-inventor of the recently filed patent. "By working with scientific/medical leaders, such as Dr. Amit Patel, the first person to inject stem cells into the human heart, we are always pushing the limits of science and coming up with approaches that one day will help patients. Being Suicide Prevention Month, we especially remember the memory of Kathleen Campbell, mother of Kalina O'Conner, a victim of suicide in whose name we started Campbell Neurosciences."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 https://www.globenewswire.com/news-rele ... Injur.html

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

https://therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy

Campbell Neurosciences Division Continues its Aggressive "Land Grab" of Suicide Prevention Intellectual Property Space


9/24/20

https://www.prnewswire.com/news-release ... 37518.html


OCEANSIDE, Calif., Sept. 24, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the launch of Neuroleukin™, a personalized biological product developed to prevent suicide.

Neuroleukin™ functions by unleashing therapeutic activities from specific cells of the patient's own blood in a manner to selectively block brain chemicals associated with suicide. The Company has demonstrated in vitro and in vivo proof of concept and is planning pilot clinical trials.

"The Neuroleukin™ approach combines products derived from the patient, as well as specifically formulated ingredients which synergistically work together to reduce brain inflammation, augment production of neurotransmitters and induce neural regeneration" said Famela Ramos, Director of Business Development and co-inventor of the patent. "We believe that the ease of generating Neuroleukin™ at the patient's bedside will allow for psychiatrists and drug rehabilitation clinics to rapidly begin implementing this new technology."

Due to the fact that Neuroleukin™ is produced from the patient's own blood, and the chemical constituents are found in the food supply, the Company believes it will not require full-blown FDA clinical trials before sales can be initiated.

"The current data supports our overarching hypothesis that neuroinflammation can be effectively suppressed by natural-based approaches" said Kalina O'Connor, Director of the Campbell Neurosciences Division of the Company and co-inventor of the patent. "We are continually developing a wide array of approaches to neuroinflammation because each patient will be different and one approach that works for one patient may not work for another."

Therapeutic Solutions International is approaching neurological diseases with a focus on regeneration. The Company has an exclusive license to the JadiCell clinical-stage universal donor stem cells for use in certain brain related conditions1.

"Neuroleukin™ is a simple, intranasal treatment, which we aim to provide the psychiatrist with an in-office intervention that works hand-in-hand with the Campbell Score™, which is the Company's proprietary method of detecting suicidal tendencies based on molecular biomarkers" said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "The potent reduction of inflammatory markers by such a small volume of administration leads our Scientific Advisory Board to believe that Neuroleukin™ may radically alter the way suicidal ideation is treated."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

[1] https://www.globenewswire.com/news-rele ... Injur.html

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell™ Universal Donor Stem Cell Therapy for Brain Injury

FDA Cleared Stem Cell is Being Utilized by TSOI as Therapeutic Candidate to Repair Damaged Brains


9/28/20


https://www.prnewswire.com/news-release ... 38937.html


OCEANSIDE, Calif., Sept. 28, 2020 /PRNewswire/ -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI), reported today positive preclinical data demonstrating superior neuro-regenerative activity to other cell therapies such as mesenchymal stem cells. Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus". Additionally, the Company reported protection of neurons from inflammation associated cell death as well as reduction of inflammatory proteins produced by brain cells called "microglia".

"These data, combined with the fact that the JadiCell has already been cleared by the FDA for clinical trials in other indications, strongly support the development of the JadiCell as a therapeutic candidate for treatment of brain injuries, including chronic traumatic encephalopathy," said Dr. James Veltmeyer, Chief Medical Officer of the Company and San Diego Top Doctor. "We are working with our team and consultants to assemble the Investigational New Drug (IND) Application with the FDA to begin clinical trials on this terrible condition."

"Brain injury in the form of Chronic Traumatic Encephalopathy is a major scourge on the bravest elements of our society: the veterans. It is estimated that approximately 1 suicide per hour occurs because of PTSD," said Famela Ramos, Former Congressional Candidate and Director of Business Development for Therapeutic Solutions International. "The fact that we are able to offer hope for this terrible condition has our whole team energized."

"To our knowledge, we are the first Company to integrate a cell therapy approach towards combatting suicide," said Kalina O'Connor Director of the Campbell Neurosciences Division of TSOI.

"Through tireless work of our Scientific Advisory Board and our collaborators, we are pleased to be moving towards filing with the FDA to begin a clinical trial which is the first of its kind. Currently there are no potentially curative approaches for Chronic Traumatic Encephalopathy," said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International announced today appointment of J Christopher Mizer to the Advisory Board of its Campbell Neurosciences Division

Suicide Prevention Focused Biotech Division Expands its Internationally Renowned Advisory Board in Preparation for Campbell Score™ Implementation

The Message that "Suicide is a Disease, not a Choice" Picks up Momentum


10/5/20

https://www.prnewswire.com/news-release ... 45596.html


OCEANSIDE, Calif., Oct. 5, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today the appointment of J Christopher Mizer to the Advisory Board of its Campbell Neurosciences Division.

Campbell Neurosciences is focused on developing a science-based approach to suicide prevention including a blood-based risk prediction test called the Campbell Score™ with an integrative nutraceutical, a drug repositioned, and a cell therapy based approach called the Campbell Protocol™. The Division is named after Kathleen Campbell, who was a victim of suicide.

"We are extremely blessed to have an individual who not only is a published scientist and has a neurosciences background, but also is internationally recognized as an entrepreneur and financier, to join us in our battle against this terrible condition" said Kalina O'Connor, Director of Campbell Neurosciences and daughter of Kathleen Campbell.

Christopher Mizer has over 25 years of extensive experience in alternative asset investing and value creation as an entrepreneur and financial expert. Mr. Mizer is the President and Chief Executive Officer of Vivaris Capital. He founded Vivaris Capital in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses in a broad range of industries that are leaders in their market niches. Vivaris also sponsors transactions in the technology and life sciences industries.

"I strongly feel that suicide is a disease, that mental illness is a disease, and that current approaches are not addressing the core causes of this condition" said Mr. Mizer. "I look forward to working with advisors such as Dr. Santosh Kesari (one of the top neurologists in the USA) and Mr. Howard Leonhardt (inventor of the stent graft that treated more than 500,000 people) in advancing the important science being developed by the Company."

"We are extremely excited to work with Mr. Mizer, who has a deep interest in science and business, but most importantly helping change the world" said Timothy Dixon, President and CEO of the Company. "Given Mr. Mizer's track record of optimizing value from potential, we are eager to initiate our collaboration which hopefully will end this terrible scourge on our society."

Prior to Vivaris Capital, Mr. Mizer served as Vice President of Key Corp. Capital Markets and Senior Accountant with Ernst & Young. He earned the Bachelor of Science and Master of Science (biology), Bachelor of Arts (economics), and Master of Business Administration (accounting and finance) degrees from Case Western Reserve University.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Launches Clinical Trial to Validate First Blood Based Predicator of Suicidal Ideation: The Campbell Score™

Clinical Stage Biotech Company Aims to Develop Biology Based Means of Assessing Suicide Risk and Providing Immunotherapy Based Interventions

Oct 29, 2020, 09:30 ET


https://www.prnewswire.com/news-release ... 63006.html


OCEANSIDE, Calif., Oct. 29, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today publication on the NIH clinical trials website1 of its newly initiated trial aiming to validate a blood-based diagnostic for predicting suicide risk.

The Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers, has previously been shown in pilot investigator-initiated studies to correlate with propensity for suicide. Based on positive feedback from collaborators, the Company decided to initiate a formal clinical trial to validate correlations between the Campbell Score™ and established psychiatric assessment tools of suicidal propensity. Currently the only means of quantifying predisposition to suicide is based on psychological, question-based techniques. These tests are highly subjective and biased based on desire of questionee to avoid being labeled as "crazy."

"I am thankful for Timothy Dixon and the team at TSOI for working to establish a biological basis of suicide as a disease and not a choice," said Kalina O'Connor, Director of the Campbell Neurosciences Division of the Company. "Rigorous scientific validation of the Campbell Score™, will be the first step in establishing a foundation for a paradigm shift in the way that suicide is approached."

Therapeutic Solutions International has previously filed patents for diagnosing people at high risk of suicide and intervening using immunotherapy and stem cell based approaches.

"According to the World Health Organization, suicide is the #2 cause of death for people between the ages of 15 and 29,"2 said Famela Ramos, Director of Business Development of the Company. "I am honored to be involved with a company that not only is working on developing the first objective means of quantifying suicidal thoughts, but also is the first to believe that taking one's life occurs because of a biochemical abnormality and not "taking the easy way out."

"The Campbell Score™ is named after Kathleen Campbell, the mother of Kalina O'Connor who was victim of suicide. We strive in her name, and the name of the multiple victims of suicide, to lay down the scientific basis, and intellectual property foundation, for repositioning suicide from a stigma to a bona fide medical condition," said Timothy Dixon, President and CEO of Therapeutic Solutions International.

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com

1 https://clinicaltrials.gov/ct2/show/NCT04606875
2 https://www.who.int/mental_health/preve ... revent/en/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder

Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac

12/9/20


https://www.prnewswire.com/news-release ... 89517.html


OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.

The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.

"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."

"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."

"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus.

"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com

1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.

ir@tsoimail.com

SOURCE
Therapeutic Solutions International

Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2310
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention
Campbell Neurosciences Division Aims to Combat Suicide-Causing Brain Inflammation using Stromal Vascular Fraction Immunotherapy


12/16/20

https://www.prnewswire.com/news-release ... 94504.html


OCEANSIDE, Calif., Dec. 16, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today signing a letter of intent with Synova Life Sciences aimed at developing a "First in Class" cellular therapy for suicide and suicidal ideation.

Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.

The two parties aim to file an Investigational New Drug (IND) application to the FDA for initiating a clinical trial in patients at high risk of suicide.

"Numerous publications have supported potent anti-inflammatory activity of stromal vascular fraction (SVF) cells 1, 2, which are rich not only in mesenchymal stem cells, but also in T regulatory cells, type 2 monocytes, and endothelial progenitor cells3," said Kalina O'Connor, Director of the Company's Campbell Neurosciences, which is focused on Suicide Prevention. "We are highly impressed by the superior speed, viability, and quality of SVF cells obtained using the Synova Life Sciences device as compared to other collagenase-based approaches. Based on this, we are eager to initiate collaborations in leveraging this device to extract the cellular fractions which we hope will be useful in reducing suicidal ideations and suicide."

"I look forward at working with the Team at Therapeutic Solutions International in advancing this novel utility of adipose derived stem cells," said John Chi, President and CEO of Synova Life Sciences. "Through collaboration with cutting edge innovators, we believe we will obtain greatest shareholder value while accelerating the progress of medicine."

"To our knowledge the Synova Device not only provides the highest quality cells, but also accomplishes this is in more rapid time than compared to other devices," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The rapid development and track record of success possessed by the team at Synova, makes them ideal partners for us as we enter this brave new world of regenerative psychiatry."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ and Campbell Neurosciences at https://www.campbellneurosciences.com

1 Bowels et al. Immunomodulatory Effects of Adipose Stromal Vascular Fraction Cells Promote Alternative Activation Macrophages to Repair Tissue Damage. Stem Cells. 2017 Oct;35(10):2198-2207.
2 Riordan et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009 Apr 24;7:29.
3 Mizer et al. Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med . 2012 Nov 21;10:231.

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
Post Reply